355 related articles for article (PubMed ID: 33896344)
1. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
[TBL] [Abstract][Full Text] [Related]
2. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
3. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
5. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
[TBL] [Abstract][Full Text] [Related]
6. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
[TBL] [Abstract][Full Text] [Related]
7. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J
N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253
[TBL] [Abstract][Full Text] [Related]
8. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK
J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248
[TBL] [Abstract][Full Text] [Related]
9. Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma.
Maciel D; Jansen JP; Klijn SL; Towle K; Dhanda D; Malcolm B; Cope S
Value Health; 2024 Apr; ():. PubMed ID: 38679290
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Connarn JN; Witjes H; van Zutphen-van Geffen M; de Greef R; Campbell TB; Hege K; Zhou S; Lamba M
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1687-1697. PubMed ID: 36794354
[TBL] [Abstract][Full Text] [Related]
11. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S; Sidana S; Shune L; Puglianini OC; Pasvolsky O; Gonzalez R; Dima D; Afrough A; Kaur G; Davis JA; Herr M; Hashmi H; Forsberg P; Sborov D; Anderson LD; McGuirk JP; Wagner C; Lieberman-Cribbin A; Rossi A; Freeman CL; Locke FL; Richard S; Khouri J; Lin Y; Patel KK; Kumar SK; Hansen DK
J Hematol Oncol; 2024 Jun; 17(1):42. PubMed ID: 38845015
[TBL] [Abstract][Full Text] [Related]
12. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
Podar K; Leleu X
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680303
[TBL] [Abstract][Full Text] [Related]
13. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Dima D; Rashid A; Davis JA; Shune L; Abdallah AO; Li H; DeJarnette S; Khouri J; Williams L; Hashmi H; Raza S; McGuirk J; Anwer F; Ahmed N
Br J Haematol; 2024 Apr; 204(4):1293-1299. PubMed ID: 38263627
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
16. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience.
Khouri J; Dima D; Li H; Hansen D; Sidana S; Shune L; Anwer F; Sborov D; Wagner C; Kocoglu MH; Atrash S; Voorhees P; Peres L; Hovanky V; Simmons G; Williams L; Raza S; Afrough A; Anderson L; Fererri C; Hashmi H; Davis J; McGuirk J; Goldsmith S; Borogovac A; Lin Y; Midha S; Nadeem O; Locke FL; Baz R; Hamilton B; Alsina M; Sauter C; Patel K; Kaur G
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38834151
[TBL] [Abstract][Full Text] [Related]
17. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC; Oswald LB; Dillard CM; De Avila G; Nishihori T; Blue BJ; Freeman CL; Locke FL; Alsina M; Castaneda Puglianini O; Shune L; Sborov DW; Wagner C; Dima D; Hashmi H; Davis JA; Kocoglu MH; Badros AZ; Atrash S; Simmons G; Kalariya N; Ferreri C; Anderson LD; Afrough A; Kaur G; Lin Y; Liu L; Nadeem O; Voorhees P; Khouri J; McGuirk J; Sidana S; Hansen DK; Patel K
Blood Adv; 2024 Jan; 8(1):251-259. PubMed ID: 37855718
[TBL] [Abstract][Full Text] [Related]
18. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
19. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.
Ferment B; Lambert J; Caillot D; Lafon I; Karlin L; Lazareth A; Touzeau C; Leleu X; Moya N; Harel S; Perrot A; Bories P; Vincent L; Lamure S; Mohty M; Malard F; Manier S; Yakoub-Agha I; Schiano De Colella JM; Brisou G; Talbot A; Decaux O; Houot R; Le Gouill S; Bigot N; Facon T; Corre J; Moreau P; Arnulf B;
Br J Haematol; 2024 May; ():. PubMed ID: 38747092
[TBL] [Abstract][Full Text] [Related]
20. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]